Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Innovent Biologics ( (HK:1801) ) has shared an update.
Innovent Biologics, Inc. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement underscores the company’s commitment to strong governance and strategic oversight, which may enhance its operational effectiveness and industry positioning.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$109.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a company incorporated in the Cayman Islands, operating within the biotechnology industry. The company focuses on developing and manufacturing biologic drugs, primarily targeting cancer and other major diseases, aiming to innovate within the healthcare sector.
Average Trading Volume: 23,906,438
Technical Sentiment Signal: Buy
Current Market Cap: HK$171.2B
For a thorough assessment of 1801 stock, go to TipRanks’ Stock Analysis page.